Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Dani Baird and her family members carry a mutated Cu,Zn-superoxide dismutase-1 (SOD1) gene, one of thirteen genes suspected of causing motor neuron diseases (MNDs). According to the National…
Scientists at École Polytechnique Fédérale de Lausanne (EPFL) have developed a small laboratory-in-a-box capable of housing and feeding a colony of C. elegans nematodes (roundworms) and testing the…
With the aid of single-cell sequencing technology, researchers at Harvard Medical School have mapped the beginnings of the biological development of both zebrafish and frogs from a single-cell…
Different types of movement disorders are difficult to distinguish due to many patients experiencing similar symptoms. Stephen Stahl, MD, discusses the differences between movement disorders, how they might…
PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain.
While there are not yet any standardized criteria for selecting candidates for deep brain stimulation (DBS) therapy, Kelvin L. Chou, MD, Co-Director of the STIM (Surgical Therapies Improving…
